The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' drug for the treatment of two serious mental health conditions, the company said on Friday, sending its shares surging 30% in ...

Researchers at the University of Seville have analyzed alterations in the cerebral cortex in people suffering from psychosis. Their findings show that psychosis does not follow a single trajectory, ...

Researchers at the University of Seville have analyzed alterations in the cerebral cortex in people suffering from psychosis.

Vanda Pharmaceuticals had 9% revenue growth and heavy losses with a 1.4x sales valuation and a PDUFA date. Check out why VNDA stock is downgraded to hold.

Newron secures up to EUR 38 million to advance its ENIGMA-TRS pivotal phase III programme: Milan, Italy Wednesday, February 18, 2026, 18:00 Hrs [IST] Newron Pharmaceuticals SpA, a ...

The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a ...

Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the potential first add-on therapy for ...

However, the opioid pathway, a heavily studied physiologic pathway inextricably intertwined with behaviour and reward, rarely receives attention within psychiatric practice. Although the opioid system ...